Dean Schorno's most recent trade in Rigel Pharmaceuticals was a trade of 7,850 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 7,850 | 7,850 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 5,625 | 5,625 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.92 per share. | 04 Feb 2025 | 2,036 | 58,969 (0%) | 0% | 20.9 | 42,595 | Common Stock |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.93 per share. | 04 Feb 2025 | 1,734 | 57,235 (0%) | 0% | 21.9 | 38,020 | Common Stock |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 19,717 | 61,005 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 14,788 | 14,788 | - | - | Employee Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 6,250 | 6,250 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2024 | 10,000 | 10,000 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 78,500 | 78,500 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 62,500 | 62,500 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.14 per share. | 02 Feb 2024 | 7,027 | 402,891 (0%) | 0% | 1.1 | 8,011 | Common Stock |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.13 per share. | 02 Feb 2024 | 5,601 | 409,918 (0%) | 0% | 1.1 | 6,327 | Common Stock |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 209,000 | 415,519 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 157,000 | 157,000 | - | - | Employee Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.66 per share. | 02 Feb 2023 | 5,389 | 196,519 (0%) | 0% | 1.7 | 8,946 | Common Stock |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 63,000 | 201,908 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 50,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 81,250 | 81,250 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP &Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Dean Schorno | EVP &Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 50,000 | 128,908 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Dean Schorno | EVP &Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 112,500 | 112,500 | - | - | Stock Option(right to buy) |